**Patient Discharge Summary**

**Patient Details:**  
Name: John Doe  
Age: 35 years  
Gender: Male  
Admission Date: November 10, 2023  
Discharge Date: November 17, 2023  
Admitting Physician: Dr. Jane Smith, MD, Infectious Diseases Unit  

**Chief Complaint:**  
The patient presented to the emergency department on November 10, 2023, with a 3-day history of high fever, cough, muscle aches, and severe fatigue. Given the symptoms and the ongoing influenza outbreak in the community, an influenza infection was suspected.

**History of Present Illness:**  
John Doe, a previously healthy 35-year-old male, began experiencing symptoms consistent with an upper respiratory tract infection, including a sore throat, non-productive cough, and malaise, which rapidly progressed to high fever (>39Â°C), pronounced muscle aches, and significant fatigue, leading to impairment in his daily activities. There was no known exposure to individuals diagnosed with influenza, but community prevalence was high.

**Medical History:**  
- No known drug allergies.  
- No chronic medical conditions.  
- Up-to-date on vaccinations, excluding the current season's influenza vaccine.

**Hospital Course:**  
Upon admission, the patient was isolated, and diagnostic tests were initiated, including a rapid antigen test for influenza, which returned positive. Given the patient's severe symptoms and the potential for complications, further testing with RT-PCR was conducted, confirming Influenza A infection. Chest x-ray and pulse oximetry were performed due to concerns of respiratory complications; findings were consistent with primary influenza pneumonia, showing interstitial infiltrates without evidence of secondary bacterial infection. The patient was started on antiviral therapy within 24 hours of symptom onset.

**Medications:**  
- **Oseltamivir** 75 mg orally twice a day was initiated on November 10, 2023, and continued for a total of 5 days. The choice of Oseltamivir was based on the patient's ability to tolerate oral medications and the lack of contraindications.
- Symptomatic treatment included **acetaminophen** 650 mg every 6 hours as needed for fever and muscle aches, and the patient was encouraged to maintain hydration and rest.

**Response to Treatment:**  
The patient demonstrated a favorable response to antiviral therapy with a gradual reduction in fever and improvement in respiratory and systemic symptoms. By Day 5 of treatment (November 15, 2023), the patient was afebrile, and significant improvement in cough and fatigue was noted. Repeat chest x-ray showed resolution of interstitial infiltrates. The patient remained in isolation until clinically stable and no longer considered infectious as per CDC guidelines.

**Discharge Instructions:**  
- Continue to rest and maintain adequate hydration at home.
- Complete the prescribed course of Oseltamivir.
- Avoid contact with immunocompromised individuals until fully recovered.
- Seek immediate medical attention if experiencing difficulty breathing, chest pain, or if symptoms reappear or worsen.
- Follow up with a primary care physician or the Infectious Diseases Unit as needed, or within 2 weeks for a post-recovery assessment.

**Preventative Measures and Recommendations:**  
- Annual influenza vaccination is strongly recommended to prevent future infections.
- Practice good hand hygiene and respiratory etiquette to reduce the risk of transmission to others.

**Follow-Up:**  
A follow-up appointment is scheduled for November 30, 2023, with Dr. Jane Smith in the Infectious Diseases Unit to ensure complete recovery and to address any ongoing health issues related to the influenza infection.

**Prepared by:**  
Dr. Jane Smith, MD  
Infectious Diseases Unit  
[Signature]  
November 17, 2023